Respiratory Syncytial Virus (RSV) Vaccine

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".

Deadline for manuscript submissions: 28 February 2025 | Viewed by 35

Special Issue Editor


E-Mail Website
Guest Editor
Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD 20993, USA
Interests: vaccines; therapeutics; antibodies; virus; animal models
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Respiratory syncytial virus (RSV) remains a significant cause of respiratory infections, particularly in infants and the elderly. Despite decades of research, vaccine development has faced significant challenges. Recent advances in vaccine technology, including viral vectors, subunit vaccines with prefusion protein designs, and mRNA-based platforms, offer promising avenues for effective and safe RSV vaccination. This Special Issue aims to highlight current understanding and explore innovative strategies to develop RSV vaccines that ensure high protection rates and long-lasting efficacy across all age groups.

Dr. Surender Khurana
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • respiratory syncytial virus (RSV)
  • RSV vaccine development
  • viral vector vaccines
  • subunit vaccines
  • prefusion protein design
  • mRNA vaccines
  • vaccine efficacy
  • immunization strategies

Published Papers

This special issue is now open for submission.
Back to TopTop